Your browser version may not work well with NCBI's Web applications. More information here...
1: Ann Trop Med Parasitol. 2006 Dec;100(8):715-31.Click here to read Links

Loiasis.

Boussinesq M.

Institut de Recherche pour le Développement (IRD), UR024, Département Sociétés et Santé, 213 rue La Fayette, 75480 Paris Cedex 10, France. boussinesq@ird.fr

Loiasis affects millions of individuals living in the forest and savannah regions of Central Africa. In some areas, this disease constitutes one of the most common reasons for medical consultation. The burden posed by loiasis is probably under-estimated and, in addition, individuals harbouring high Loa microfilarial loads are at risk of developing serious neurological reactions after treatment with diethylcarbamazine or ivermectin. These events are currently significantly hampering the development of the African Programme for Onchocerciasis Control, and operational research is required to address the issue. The results of recent studies, involving either human populations from endemic areas or monkey models, have provided much more detail of the mechanisms associated with amicrofilaraemic or so-called 'occult' loiasis. New diagnostic tools have also been developed in the last decade, and various protocols are now available for the risk-free treatment of loiasis cases.

PMID: 17227650 [PubMed - indexed for MEDLINE]

Patient Drug Information

  • Ivermectin (Stromectol® )

    Ivermectin is used to treat strongyloidiasis (threadworm; infection with a type of roundworm that enters the body through the skin, moves through the airways and lives in the intestines). Ivermectin is also used to contr...

  • Source: AHFS Consumer Medication Information

Recent Activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on